BioMimetic Therapeutics, Inc. specializes in the development and commercialization of products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic and sports medicine applications. The Company’s augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is a bioengineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. The Company engages in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments. The Company's initial focus in orthopedics is the development of Augment Bone Graft (rhPDGF/Beta-TCP) as a substitute for autograft in foot and ankle fusions. The Company’s product is AUGMENT BONE GRAFT. Augment Bone Graft is a bioengineered alternative to autograft in orthopedic surgery (non-human origin).